PROTEINA
29.4.2024 06:18:35 CEST | Business Wire | Press release
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
illumynt Appoints Anthony Giannetti as Senior Vice President of Global Operations16.7.2026 13:00:00 CEST | Press release
Seasoned operations leader brings two decades of OEM and ITAD experience, including Dell, Apple, and Microsoft, as illumynt scales its global AI hardware lifecycle platform illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Anthony "Tony" Giannetti has joined the company as Senior Vice President of Global Operations, effective July 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716696044/en/ Anthony Giannetti, SVP Global Operations Giannetti brings more than two decades of operations and supply chain leadership from some of the technology industry's largest OEMs, including Dell, where he managed reverse supply chain operations, and Apple and Microsoft, where he held additional operations leadership roles. His background spans production engineering, reverse logistics, and large-scale operational management, disciplines directly relevant to
Compvide™ Announces Strategic Collaboration with OpZira™ to Accelerate Growth and Advance the CIMED™ Platform16.7.2026 12:47:00 CEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 12:35:00 CEST | Press release
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapyFindings published in the Journal of Psychopharmacology Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this fo
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 12:04:00 CEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 11:21:00 CEST | Press release
Founded in Europe, now with global reach: backed by European investors and bringing bank-grade European compliance standards to markets worldwide Customer Value: A streamlined, end-to-end user experience that protects identity across the entire customer lifetime and helps customers grow revenue safely and compliantly. The Expected Result:Fourthline and Veridas are joining forces to create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US. One trusted partner for end-to-end KYC, AML, and Identity compliance. Terms of Deal: Following completion of the merger, Veridas shareholders (including BBVA) will continue as shareholders in the combination, and the transaction will be partially funded by existing Fourthline investor Finch Capital and new investors including Rabo Investments, the captive investment arm of Rabobank. Expected close is in the second half of 2026, pending c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom